Acromegaly Biochemical Diagnosis (IGF-1 + OGTT)

Interprets the biochemical tests for acromegaly.

Open the calculator → Runs in your browser. Data leaves only if you deliberately send a problem report from the interactive tool.

Example

IGF-1 as a multiple of the age- and sex-matched upper limit
2.0
IGF-1 interpreted against an age- and sex-matched range
Yes
Typical clinical features present
Yes

Result: Confirmatory of acromegaly

The tool opens with these values already filled in. Replace them with your own.

What the result means

Confirmatory
IGF-1 above 1.3 times the age- and sex-matched upper limit of normal, together with typical clinical features.
Excluded
A normal age- and sex-matched IGF-1 WITH a suppressed growth hormone nadir on the 75 g oral glucose tolerance test.
The assay decides
The nadir threshold is below 1.0 micrograms/L on a conventional assay and below 0.4 on an ultrasensitive one. One figure used for both gets one of them wrong.
Random GH
Not a diagnostic test. Growth hormone is secreted episodically, and the guideline recommends against single random measurements.
What a random can do
Contribute to EXCLUSION only, and only below 0.4 micrograms/L alongside a normal IGF-1. A raised random level supports nothing on its own.
Both halves
Exclusion needs both. A suppressed nadir with a raised IGF-1 does not exclude acromegaly, and a normal IGF-1 with an unsuppressed nadir does not establish it.
Discordance
A result in its own right, calling for further evaluation rather than a verdict.
Age-matched or useless
IGF-1 falls with age, so a laboratory range that is not age- and sex-specific cannot answer this question at all.

What you enter

  • IGF-1 as a multiple of the age- and sex-matched upper limit
  • IGF-1 interpreted against an age- and sex-matched range
  • Typical clinical features present
  • OGTT growth hormone nadir, micrograms/L
  • Growth hormone assay
  • Random growth hormone, micrograms/L
How this is calculated

Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933-3951. Ultrasensitive-assay nadir: Giustina A, Barkan A, Beckers A, et al. Pituitary. 2024;27(1):7-22. Read the source ↗

A reference and educational tool. Not medical, legal, or financial advice, and not a substitute for clinician judgment.

Browse all tools

Built by Clay Good. Source on GitHub.